DrugPatentWatch Database Preview

Emd Serono Inc Company Profile

Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for EMD SERONO INC, and when can generic versions of EMD SERONO INC drugs launch?

EMD SERONO INC has five approved drugs.

There are four US patents protecting EMD SERONO INC drugs.

There are one hundred and eleven patent family members on EMD SERONO INC drugs in thirty-three countries and fifty-eight supplementary protection certificates in sixteen countries.

Summary for Emd Serono Inc

International Patents:	111
US Patents:	4
Tradenames:	5
Ingredients:	4
NDAs:	5
Drug Master File Entries:	2

Drugs and US Patents for Emd Serono Inc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Emd Serono Inc	GLUCOPHAGE XR	metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021202-004	Apr 11, 2003		DISCN	Yes	No
Emd Serono Inc	GLUCOPHAGE	metformin hydrochloride	TABLET;ORAL	020357-003	Nov 5, 1998		DISCN	Yes	No
Emd Serono Inc	GLUCOPHAGE XR	metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021202-001	Oct 13, 2000		DISCN	Yes	No
Emd Serono Inc	MAVENCLAD	cladribine	TABLET;ORAL	022561-001	Mar 29, 2019		RX	Yes	Yes	7,713,947
Emd Serono Inc	MAVENCLAD	cladribine	TABLET;ORAL	022561-001	Mar 29, 2019		RX	Yes	Yes	7,888,328		Y
Emd Serono Inc	CETROTIDE	cetrorelix	INJECTABLE;INJECTION	021197-002	Aug 11, 2000		DISCN	No	No
Emd Serono Inc	GEREF	sermorelin acetate	INJECTABLE;INJECTION	020443-002	Sep 26, 1997		DISCN	Yes	No

Expired US Patents for Emd Serono Inc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Emd Serono Inc	GEREF	sermorelin acetate	INJECTABLE;INJECTION	020443-001	Sep 26, 1997	4,517,181
Emd Serono Inc	CETROTIDE	cetrorelix	INJECTABLE;INJECTION	021197-001	Aug 11, 2000	6,319,192
Emd Serono Inc	CETROTIDE	cetrorelix	INJECTABLE;INJECTION	021197-001	Aug 11, 2000	4,800,191
Emd Serono Inc	CETROTIDE	cetrorelix	INJECTABLE;INJECTION	021197-002	Aug 11, 2000	7,605,121
Emd Serono Inc	GLUCOPHAGE XR	metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021202-004	Apr 11, 2003	6,660,300
Emd Serono Inc	CETROTIDE	cetrorelix	INJECTABLE;INJECTION	021197-002	Aug 11, 2000	4,800,191
Emd Serono Inc	GEREF	sermorelin acetate	INJECTABLE;INJECTION	020443-001	Sep 26, 1997	4,703,035

International Patents for Emd Serono Inc Drugs

Country	Patent Number	Estimated Expiration
Spain	2382554
Montenegro	00249
Singapore	160391
Australia	2011200768
Brazil	PI0408848
Hungary	S1800013
Serbia	20050735

Supplementary Protection Certificates for Emd Serono Inc Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1506211	132014902277722	Italy		PRODUCT NAME: UNA COMBINAZIONE DI DAPAGLIFLOZIN O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE E METFORMINA O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE COME PROTETTI DAL BREVETTO DI BASE EP1506211(XIGDUO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/13/900, 20140116
1412357	50/2008	Austria		PRODUCT NAME: SITAGLIPTIN, GEGEBENENFALLS IN DER FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE ALS MONOPHOSPHAT, UND METFORMIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE DES HYDROCHLORIDS; NAT. REGISTRATION NO/DATE: EU/1/08/455/001-014, EU/1/08/456/001-014, EU/1/08/457/001-014 20080716; FIRST REGISTRATION: CH 58450 01-03 20080408
1412357	PA2008013	Lithuania		PRODUCT NAME: SITAGLIPTINUM PHOSPHAS MONOHYDRICUS, METFORMINI HYDROCHLORIDUM; REG. NO/DATE: EU/1/08/455/001-014 20080716
1412357	C 2008 016	Romania		PRODUCT NAME: SITAGLIPTIN OPTIONAL SUB FORMA DE SARE ACCEPTABILAFARMACEUTIC IN SPECIAL MONOFOSFAT + METFORMIN OPTIONAL SUB FORMA DE SARE ACCEPTABILA FARMACEUTIC IN SPECIALCLORHIDRAT; NATIONAL AUTHORISATION NUMBER: RO EU/1/08/455/001 - RO EU/1/08/455/014; DATE OF NATIONAL AUTHORISATION: 20080716; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): CH 58450 01, CH 58450 02, CH 58450 03; DATE OF FIRST AUTHORISATION IN EEA: 20080408
1261586	C300524	Netherlands		PRODUCT NAME: COMBINATIE VAN SAXAGLIPTINE EN METFORMINE, DESGEWENST IN DE VORM VAN FARMACEUTISCH AANVAARDBARE AFGELEIDEN DAARVAN; NAT. REGISTRATION NO/DATE: EU/1/11/731/001-012 20111124; FIRST REGISTRATION:
1412357	SPC/GB08/040	United Kingdom		PRODUCT NAME: SITAGLIPTIN OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR THE MONOPHOSPHATE, PLUS METFORMIN OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR THE HYDROCHLORIDE.; REGISTERED: CH 58450 01-03 20080408; UK EU/1/08/455/001 20080716; UK EU/1/08/455/002 20080716; UK EU/1/08/455/003 20080716; UK EU/1/08/455/004 20080716; UK EU/1/08/455/005 20080716; UK EU/1/08/455/006 20080716; UK EU/1/08/455/007 20080716; UK EU/1/08/455/008 20080716; UK EU/1/08/455/009 20080716; UK EU/1/08/455/010 20080716; UK EU/1/08/455/011 20080716; UK EU/1/08/455/012 20080716; UK EU/1/08/455/013 20080716; UK EU/1/08/455/014 20080716
1412357	CA 2008 00035	Denmark		PRODUCT NAME: SITAGLIPTIN VALGFRIT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, ISAER MONOPHOSPHAT, METFORMIN VALGFRIT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, ISAER HYDROCHLORID

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Emd Serono
• Emd Serono Inc